Coronary Occlusions Pipeline Analysis Report 2026

Report Coverage

The Coronary Occlusions Pipeline Analysis Report by Expert Market Research gives comprehensive insights into coronary occlusions therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for coronary occlusions. The coronary occlusions report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The coronary occlusions pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with coronary occlusions treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to coronary occlusions.

Read more about this report - Request a Free Sample

Coronary Occlusions Pipeline Outlook

Coronary occlusions, blockages in the heart’s arteries disrupting blood flow, are typically treated with percutaneous coronary intervention (PCI) using drug-eluting stents (DES) to reopen narrowed vessels and prevent restenosis.

Coronary occlusion treatment is evolving with the introduction of device-based innovations that aim to reduce long-term complications associated with permanent implants. Emerging therapies such as drug-coated balloons (DCBs) offer non-metallic alternatives to stents, particularly for small and complex lesions. In August 2025, Boston Scientific initiated the global STANCE trial evaluating the AGENT drug-coated balloon, the only FDA-approved coronary DCB, in de novo coronary lesions. The study targets small vessels, bifurcations, and long lesions, enrolling over 1,600 patients, potentially expanding DCB use beyond in-stent restenosis and reshaping future coronary occlusion treatment paradigms.

Coronary Occlusions Epidemiology

Coronary occlusions are a major component of ischemic heart disease (IHD), a condition resulting from blocked coronary arteries that restrict blood flow to the heart muscle. As per the American Heart Association, 254.3 million people were affected globally in 2021, causing 8.99 million deaths that year, making IHD one of the leading causes of mortality worldwide. Age‑standardized IHD death rates were highest in Central Asia, Eastern Europe, and North Africa/Middle East, reflecting significant regional disparities in disease burden and healthcare access. The global IHD prevalence and mortality continue to rise, remaining substantial drivers of cardiovascular health loss, with males generally more affected than females.

Coronary Occlusions – Pipeline Therapeutic Assessment

Coronary Occlusions Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total coronary occlusions clinical trials. The pipeline comprises 20% of phase II, 28% of phase III, and 44% of phase IV studies, reflecting a strong emphasis on late-stage development. The higher proportion of Phase 3 and 4 trials indicates significant clinical validation and readiness for widespread therapeutic adoption in real-world cardiovascular management.

Coronary Occlusions Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the coronary occlusions pipeline analysis include monoclonal antibodies, small molecules, and peptides. The coronary occlusions report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for coronary occlusions. In July 2025, CorFlow announced FDA approval to initiate the pivotal MOCA‑II IDE trial, evaluating its CoFl system for diagnosing and managing microvascular obstruction (MVO) during primary PCI in STEMI patients. This trial targets improved outcomes after reopening occluded coronary arteries, representing a significant advancement in the coronary occlusions treatment pipeline.

Coronary Occlusions Clinical Trials – Key Players

The EMR report for the coronary occlusions pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed coronary occlusions therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in coronary occlusions clinical trials:

• Beijing Inno Medicine Co., Ltd.
• Hexun Biosciences Co., Ltd.
• Insight Lifetech Co., Ltd.
• XyloCor Therapeutics, Inc.
• Cyclarity Therapeutics, Inc.
• Verve Therapeutics, Inc.
• Honya Medical Inc.
• Novartis Pharmaceuticals
• GE Healthcare
• Hanmi Pharmaceutical Co., Ltd.

Coronary Occlusions – Emerging Drugs Profile

Key Questions Answered in the Coronary Occlusions Pipeline Insight Report

• Which companies/institutions are leading the coronary occlusions drug development?
• Which company is leading the coronary occlusions pipeline development activities?
• What is the current coronary occlusions commercial assessment?
• What are the opportunities and challenges present in the coronary occlusions pipeline landscape?
• What is the efficacy and safety profile of coronary occlusions pipeline drugs?
• Which company is conducting major trials for coronary occlusion drugs?
• Which companies/institutions are involved in coronary occlusions collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in coronary occlusions?

Reasons To Buy This Report

The Coronary Occlusions Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for coronary occlusions. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into coronary occlusions collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Acute Coronary Syndrome Pipeline Analysis Report

Acute Coronary Syndrome Treatment Market

Coronary Artery Disease (CAD) Epidemiology Forecast